Ucb Biopharma Sprl

Boehringer Ingelheim International Gmbh

Ucbbiopharma Srl

James Madden

Matthew Duncan Selby

John Robert Porter

Daniel Christopher Brookings

Craig Johnstone

Jonathan Bentley

Jonathan Mark Bentley

Zhaoning Zhu

Boris Kroeplien

Julien Alistair Brown

Victoria Elizabeth Jackson

Fabien Claude Lecomte

Michael Alan Shaw

Laura Gleave

Alexander Heifetz

Deborah Leigh

Thomas Paul Cain

Laura Jane Gleave

Rikki Peter Alexander

Timothy John Norman

James Andrew Johnson

Martin Clive Hutchings

James Thomas Reuberson

Judi Charlotte Neuss

Jag Paul Heer

Ulrich Reiser

Elizabeth Pearl Jones

Helen Tracey Horsley

Martin Alexander Lowe

Joanna Rachel Quincey

Richard Jeremy Franklin

Gareth Neil Brace

Alistair James Henry

Anne Marie Foley

Ian Yule

William Ross Pitt

Ellen Olivia Gallimore

Oliver Philps

Prafulkumar Tulshibhai Chovatia

Giancarlo Trani

Hervé Jean Claude Deboves

Gregory William Haslett

Selvaratnam Suganthan

Rickki Lee Connelly

Konstantinos Rampalakos

Craig Miller

Pfrafulkumar Tulshibhai Chovatia

Sarah Emily Richardson

Anthony John Richardson

Laura Claire Reed

Praful Tulshi Chovatia

Darshan Gunvant Vaidya

Craig Adrian Miller

Ian Andrew Yule

Herve Jean Deboves

Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

Thiophene derivatives for the treatment of disorders caused by IgE

A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused imidazole and pyrazole derivatives as modulators of TNF activity

A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. The imidazo[1,2-a]pyrazine derivatives of the disclosure are of general formula 

Substituted imidazo[1,2-a]pyrazines as TNF activity modulators

A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 

Imidazopyridine derivatives as modulators of TNF activity

This invention relates to 6-alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups Rto Rhave the meanings given in the claims and in the specification.

6-Alkynyl Pyridine

Growing community of inventors

Abingdon, United Kingdom

James Madden